Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Node-Sparing RT for MSS Colon Cancer
NCT06594692Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in colon cancer, sponsored by Sir Run-Run Shaw Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06594692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594692.